HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lautenberg Plans TSCA Update Bill For 113th Congress

This article was originally published in The Rose Sheet

Executive Summary

Introducing a bill to modernize the 36-year-old Toxic Substances Control Act is a priority for Sen. Frank Lautenberg, D-N.J., in the 113th Congress.

You may also be interested in...



Chemical Safety Improvement Act Promises Stronger EPA Oversight

Introduced by New Jersey Sen. Frank Lautenberg, the Chemical Safety Improvement Act of 2013 would give EPA authority to evaluate chemicals in commerce based on risk to human health and the environment and take action on those deemed unsafe. The bill would update the current Toxic Substances Control Act and potentially impact manufacturers of cosmetic ingredients.

In Brief

Living Proof says it will expand its existing business and fuel R&D with $30 million in new funds from investors; Sen. Frank Lautenberg announces his plan to retire in 2014, with TSCA reform cited as a priority to cap his career. More news in brief.

In Brief

Senator Frank Lautenberg’s TSCA reform bill, the Safe Chemicals Act, advances through the Senate Environmental and Public Works Committee. More news in brief.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS018531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel